Atlas Trials

Autologous T Cells Redirected to EGFRVIII-With a Chimeric Antigen Receptor in Patients With EGFRVIII+ Glioblastoma

Clinical trial NCT02209376 · TERMINATED

Trial details

NCT number
NCT02209376
Sponsor
University of Pennsylvania
Status
TERMINATED
Phase
Phase 1
Study type
INTERVENTIONAL
Patients With Residual or Reccurent EGFRvIII+ Glioma
Start date
2014-11-18
Primary completion
2018-04-04
Enrollment
11

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.